Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
足细胞形成血管紧张素代谢物:对肾小球损伤的影响
基本信息
- 批准号:7449966
- 负责人:
- 金额:$ 14.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-01 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAmericanAngiotensin IIAngiotensinsAwardBasic ScienceBuffersCellsCellular biologyChronic Kidney FailureClinicalCollagen Type IVComplexDataDepositionDiabetic NephropathyDiseaseEndothelial CellsEnhancersEnsureEnvironmentEnzymesEquilibriumExtracellular Matrix ProteinsExtramural ActivitiesFactor VFibronectinsFocal Segmental GlomerulosclerosisFoundationsFunctional disorderFundingFutureGene TargetingGenerationsGoalsHormonesImage AnalysisImmune Complex GlomerulonephritisImmunoglobulin AIn VitroIndividualInjuryJournalsKidneyKidney DiseasesKidney GlomerulusKnockout MiceKnowledgeLaboratoriesLaboratory ResearchLeadLinkLongevityMass Spectrum AnalysisMediatingMediator of activation proteinMedicalMentorsMentorshipMetabolismNephrologyNeprilysinNuclear Magnetic ResonanceOrganPathway interactionsPatientsPatternPeer ReviewPeptidesPeptidyl-Dipeptidase APlasminogen Activator Inhibitor 1PlayProcessPublic HealthPublicationsPurposeQualifyingRecordsRegulationRenal CirculationRenin-Angiotensin SystemResearchResearch PersonnelResearch ProposalsResource SharingResourcesRiskRoleScientistSeriesSourceSouth CarolinaStagingSystemTestingTherapeuticTimeTrainingTransforming Growth FactorsUltrafiltrationUniversitiescareercell injurycell typeconnective tissue growth factordesignenzyme activityexperienceglutamyl aminopeptidasehormone regulationimprovedin vivoinsightmesangial cellmultidisciplinarypodocyteprofessorprogramsreceptorresearch study
项目摘要
DESCRIPTION (provided by applicant):
This is a new K08 application, the purpose of which is to provide training and a mentored research environment for the candidate, Dr. Juan Carlos Q. Velez, at the Medical University of South Carolina. MUSC is part of South Carolina's largest medical complex with 140,000 ft2 dedicated to research laboratory space and a multidisciplinary University Research Resource Facility (URRF) that contains shared resources available to investigators including: Advanced Image Analysis; Gene targeting and Knockout Mouse Facility; Nuclear Magnetic Resonance Facility, and an established Mass Spectrometry Facility.
Candidate. The candidate is a new full-time tenure-track assistant professor in the Division of Nephrology, at the MUSC. He is an up-and-coming young clinician-scientist that has a track record of two awards in basic science research during his early career and one recent first-author publication in a prestigious peer-reviewed journal. He possesses professional qualities highly suited for KO8 sponsorship. Dr. Velez has outlined a plan to develop a successful independently funded laboratory and to gain experience necessary to maintain a productive scientific career relevant to kidney research. To ensure these goals are met, Dr. Velez has assembled a highly qualified mentorship committee of scientists who have extensive track records in obtaining extramural funding and maintaining successful research laboratories.
Research Proposal. The proposal has been designed to include a focused hypothesis-driven series of experiments that will yield insight into mechanisms of hormonal regulation within the kidney glomerulus and their relationship with pathways that lead to progressive kidney diseases. Specifically, the proposal is focused on examining the balance between intraglomerular angiotensin-II and other angiotensin metabolites and the role that glomerular podocytes play in that system. The goal of the research proposal is to establish a foundation of technical knowledge and expertise by which a long-term research program can be established.
PUBLIC HEALTH RELEVANCE: The studies outlined herein will add to the understanding of the existing mechanisms within the kidney to counterbalance the actions of the hormone angiotensin-II. Twenty million American have chronic kidney disease and many others are on risk of acquiring it. Pharmacological blockade of angiotensin-II constitutes the only FDA-approved therapy available. Despite receiving this therapy, a significant percentage of the affected patients continue to progress to the end-stage form of the disease. Better understanding of the mechanisms of in the kidney should lead to therapies that can directly target. These therapies would improve both quality and length of life of affected individuals.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Juan Carlos Q. Velez其他文献
Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1
在 1 型肝肾综合征治疗期间向去甲肾上腺素中添加袢利尿剂
- DOI:
10.1016/j.ekir.2024.11.013 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:5.700
- 作者:
Juan Carlos Q. Velez;Terrance J. Wickman;Kasra Tayebi;Muner M.B. Mohamed;Adil Yousuf;Swetha R. Kanduri;Ivo Lukitsch;Derek Vonderhaar;Karthik Kovvuru;Cathy Wentowski - 通讯作者:
Cathy Wentowski
International cross-sectional survey on current and updated definitions of intra-abdominal hypertension and abdominal compartment syndrome
- DOI:
10.1186/s13017-024-00564-5 - 发表时间:
2024-11-29 - 期刊:
- 影响因子:5.800
- 作者:
Prashant Nasa;Robert D. Wise;Marije Smit;Stefan Acosta;Scott D’Amours;William Beaubien–Souligny;Zsolt Bodnar;Federico Coccolini;Neha S. Dangayach;Wojciech Dabrowski;Juan Duchesne;Janeth C. Ejike;Goran Augustin;Bart De Keulenaer;Andrew W. Kirkpatrick;Ashish K. Khanna;Edward Kimball;Abhilash Koratala;Rosemary K. Lee;Ari Leppaniemi;Edgar V. Lerma;Valerie Marmolejo;Alejando Meraz–Munoz;Sheila N. Myatra;Daniel Niven;Claudia Olvera;Carlos Ordoñez;Clayton Petro;Bruno M. Pereira;Claudio Ronco;Adrian Regli;Derek J. Roberts;Philippe Rola;Michael Rosen;Gentle S. Shrestha;Michael Sugrue;Juan Carlos Q. Velez;Ron Wald;Jan De Waele;Annika Reintam Blaser;Manu L. N. G. Malbrain - 通讯作者:
Manu L. N. G. Malbrain
Renal Physiology Education via Podcast: Channel Your Enthusiasm
- DOI:
10.1016/j.xkme.2024.100903 - 发表时间:
2024-11-01 - 期刊:
- 影响因子:
- 作者:
Melanie P. Hoenig;Anna R. Gaddy;Priti Meena;Roger A. Rodby;Leticia Rolón;Juan Carlos Q. Velez;Joshua Waitzman;Amy A. Yau;Joel M. Topf - 通讯作者:
Joel M. Topf
Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis
重新评估肝硬化患者急性肾损伤和肝肾综合征的频谱
- DOI:
10.1038/s41581-019-0218-4 - 发表时间:
2019-11-13 - 期刊:
- 影响因子:39.800
- 作者:
Juan Carlos Q. Velez;George Therapondos;Luis A. Juncos - 通讯作者:
Luis A. Juncos
Juan Carlos Q. Velez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Juan Carlos Q. Velez', 18)}}的其他基金
Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
足细胞形成血管紧张素代谢物:对肾小球损伤的影响
- 批准号:
8032666 - 财政年份:2010
- 资助金额:
$ 14.95万 - 项目类别:
Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
足细胞形成血管紧张素代谢物:对肾小球损伤的影响
- 批准号:
7886521 - 财政年份:2008
- 资助金额:
$ 14.95万 - 项目类别:
Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
足细胞形成血管紧张素代谢物:对肾小球损伤的影响
- 批准号:
7622073 - 财政年份:2008
- 资助金额:
$ 14.95万 - 项目类别:
Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
足细胞形成血管紧张素代谢物:对肾小球损伤的影响
- 批准号:
8628472 - 财政年份:2008
- 资助金额:
$ 14.95万 - 项目类别:
Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
足细胞形成血管紧张素代谢物:对肾小球损伤的影响
- 批准号:
8279359 - 财政年份:2008
- 资助金额:
$ 14.95万 - 项目类别:
Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
足细胞形成血管紧张素代谢物:对肾小球损伤的影响
- 批准号:
8103946 - 财政年份:2008
- 资助金额:
$ 14.95万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 14.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 14.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 14.95万 - 项目类别:














{{item.name}}会员




